Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Infectious diseases
- Publicado em
- 9 ago 2024
- Citações
- 113
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial
Paul Kim, Ana M Sanchez, Taylor J R Penke, Hannah H Tuson, James C Kime, Robert W McKee, William L Slone, Nicholas R Conley, Lana J McMillan, Cameron J Prybol et al.
Descritores MeSH
- Anti-Bacterial Agents
- Urinary Tract Infections
- Escherichia coli
- Escherichia coli Infections
- Bacteriophages
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
Veja também
Estudos relacionados
- Phage therapy in patients with urinary tract infections: a systematic review
- A Randomized, Placebo-controlled, Double-blind Clinical Trial of Bacteriophage Cocktails in Chronic Wound Infections
- Global prevalence of fluoroquinolone resistance in Escherichia coli causing urinary tract infections: a systematic review and meta-analysis
- E. coli as a uropathogen in patients with diabetes mellitus, its prevalence and antimicrobial resistance profile in Ethiopia: A systematic review and meta-analysis